Search research articles
Contact Us
Filters
Showing results (771-780 of 903) with videos related to
Page
of 91
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 25, 2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function
Andrew Stiff, Prashant Trikha, Bethany Mundy-Bosse, et al.
Leukemia
|
June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Z A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia
|
July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood
|
January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Haematologica
|
May 6, 2017
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, et al.
Journal of the American Heart Association
|
September 19, 2025
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation
Cooper Quartermaine, Zach Braunstein, Adnan Shaaban, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2009
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
Shih-Shih Chen, Aparna Raval, Amy J Johnson, et al.
Blood
|
September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C Byrd, Thomas S Lin, James T Dalton, et al.
Blood
|
May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
William Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood Advances
|
January 4, 2018
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, et al.
Page
of 91
Search research articles
Search
Showing results (771-780 of 903) with videos related to
Sort By:
Page
of 91
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 25, 2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function
Andrew Stiff, Prashant Trikha, Bethany Mundy-Bosse, et al.
Leukemia
|
June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Z A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia
|
July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood
|
January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Haematologica
|
May 6, 2017
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, et al.
Journal of the American Heart Association
|
September 19, 2025
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation
Cooper Quartermaine, Zach Braunstein, Adnan Shaaban, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2009
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
Shih-Shih Chen, Aparna Raval, Amy J Johnson, et al.
Blood
|
September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C Byrd, Thomas S Lin, James T Dalton, et al.
Blood
|
May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
William Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood Advances
|
January 4, 2018
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, et al.
Page
of 91